Positive trial results for RSV infant treatment: Sanofi
French pharmaceutical giant Sanofi announced trial results on Friday that showed its preventative treatment for respiratory syncytial virus (RSV) reduced the rate of babies being hospitalised by more than 80 percent.. The results showed an 83 percent reduction in hospitalisations for infants with RSV-related illnesses who received a single dose of nirsevimab, compared to a control group who did not receive the treatment.